Jiangsu Vcare Pharmaceutical Technology Co., Ltd

This study is testing whether an oral tablet called VC005 can help reduce the white skin patches caused by non-segmental vitiligo, primarily on the face. It will involve about 120 adults and compare the new tablet against a placebo over 24 weeks to see if it's safe and effective.…

This large, late-stage study is testing whether a new tablet called VC005 can help control the painful inflammation and stiffness of active ankylosing spondylitis. It will involve 420 adults with the condition to see if the drug safely improves their symptoms. The main goal is to…

This early-stage study is testing a new gel called VC005 for teens with mild to moderate eczema (atopic dermatitis). The main goals are to check how safe it is and how the body processes it. The study will involve a small group of 10 participants aged 12 to 18.